Park­er col­lab­o­ra­tor Tes­sa al­lies with St. Jude, launch­es a new T cell pro­gram for pe­di­atric brain can­cer

Af­ter pick­ing up some high-pro­file al­lies at the Park­er In­sti­tute, where top sci­en­tists have be­come en­am­ored with its virus-spe­cif­ic ap­proach to de­vel­op­ing new can­cer cell ther­a­pies, Sin­ga­pore-based Tes­sa Ther­a­peu­tics is launch­ing a new de­vel­op­ment pro­gram for brain can­cer in the US.

In a tie-up with St. Jude Chil­dren’s, Tes­sa will use its plat­form tech to de­vel­op a mul­ti-anti­gen strat­e­gy for high-grade gliomas, start­ing with the kids at the hos­pi­tal. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER